Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

IDYABullishCorporate Developmentsnews

High materiality9/10

IDEAYA advances darovasertib NDA under RTOR; strong cash runway into 2030

Aug 4, 2026, 6:06 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Key regulatory milestone (NDA under RTOR) and substantial cash runway reduce execution risk, while multiple near-term data readouts and a Roche collaboration create multiple positive catalysts.

AI summary

What happened, with direct paths to the underlying reporting

IDEAYA reported Q2 2026 results with a positive OptiUM-02 topline: the darovasertib combination met its primary endpoint, enabling NDA submission under RTOR with completion anticipated in H2 2026. The company will present updated OptimUM-01 and OptimUM-09 data at ESMO and is advancing IDE849 and IDE892 programs, plus Roche collaboration; cash on hand supports operations into 2030 and multiple data milestones in 2026.

OptimUM-02 met primary endpoint; NDA under RTOR with H2 2026 completion.
ESMO to present OptimUM-01 and OptimUM-09 updated data.
IDE849 DLL3 ADC data updates at ESMO; first global data in 2H 2026.
Roche collaboration to evaluate IDE892 with RG6505 in MTAP-del, RAS-mutant PDAC; Phase 1 in 2H 2026.
Cash runway to 2030; IDEAYA to host R&D Day in Q4 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.